Year |
Citation |
Score |
2021 |
Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy. Nature Communications. 12: 7128. PMID 34880230 DOI: 10.1038/s41467-021-27430-1 |
0.642 |
|
2018 |
Zhang X, Yoon JY, Morley M, McLendon JM, Mapuskar KA, Gutmann R, Mehdi H, Bloom HL, Dudley SC, Ellinor PT, Shalaby AA, Weiss R, Tang WHW, Moravec CS, Singh M, ... ... Boudreau RL, et al. A common variant alters SCN5A-miR-24 interaction and associates with heart failure mortality. The Journal of Clinical Investigation. PMID 29457789 DOI: 10.1172/Jci95710 |
0.328 |
|
2017 |
Kim YC, Miller A, Lins LC, Han SW, Keiser MS, Boudreau RL, Davidson BL, Narayanan NS. RNA Interference of Human α-Synuclein in Mouse. Frontiers in Neurology. 8: 13. PMID 28197125 DOI: 10.3389/Fneur.2017.00013 |
0.526 |
|
2016 |
Spengler RM, Zhang X, Cheng C, McLendon JM, Skeie JM, Johnson FL, Davidson BL, Boudreau RL. Elucidation of transcriptome-wide microRNA binding sites in human cardiac tissues by Ago2 HITS-CLIP. Nucleic Acids Research. PMID 27418678 DOI: 10.1093/Nar/Gkw640 |
0.742 |
|
2015 |
Piedrahita D, Castro-Alvarez JF, Boudreau RL, Villegas-Lanau A, Kosik KS, Gallego-Gomez JC, Cardona-Gómez GP. β-Secretase 1's Targeting Reduces Hyperphosphorilated Tau, Implying Autophagy Actors in 3xTg-AD Mice. Frontiers in Cellular Neuroscience. 9: 498. PMID 26778963 DOI: 10.3389/Fncel.2015.00498 |
0.303 |
|
2015 |
Madhavan L, Daley BF, Davidson BL, Boudreau RL, Lipton JW, Cole-Strauss A, Steece-Collier K, Collier TJ. Sonic Hedgehog Controls the Phenotypic Fate and Therapeutic Efficacy of Grafted Neural Precursor Cells in a Model of Nigrostriatal Neurodegeneration. Plos One. 10: e0137136. PMID 26340267 DOI: 10.1371/Journal.Pone.0137136 |
0.508 |
|
2015 |
Monteys AM, Wilson MJ, Boudreau RL, Spengler RM, Davidson BL. Artificial miRNAs Targeting Mutant Huntingtin Show Preferential Silencing In Vitro and In Vivo. Molecular Therapy. Nucleic Acids. 4: e234. PMID 25849618 DOI: 10.1038/Mtna.2015.7 |
0.778 |
|
2014 |
Lee JH, Sowada MJ, Boudreau RL, Aerts AM, Thedens DR, Nopoulos P, Davidson BL. Rhes suppression enhances disease phenotypes in Huntington's disease mice. Journal of Huntington's Disease. 3: 65-71. PMID 25062765 DOI: 10.3233/Jhd-140094 |
0.581 |
|
2014 |
Ramachandran PS, Boudreau RL, Schaefer KA, La Spada AR, Davidson BL. Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1635-42. PMID 24930601 DOI: 10.1038/Mt.2014.108 |
0.774 |
|
2014 |
Ramachandran PS, Bhattarai S, Singh P, Boudreau RL, Thompson S, Laspada AR, Drack AV, Davidson BL. RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration. Plos One. 9: e95362. PMID 24759684 DOI: 10.1371/Journal.Pone.0095362 |
0.755 |
|
2014 |
Gross TJ, Powers LS, Boudreau RL, Brink B, Reisetter A, Goel K, Gerke AK, Hassan IH, Monick MM. A microRNA processing defect in smokers' macrophages is linked to SUMOylation of the endonuclease DICER. The Journal of Biological Chemistry. 289: 12823-34. PMID 24668803 DOI: 10.1074/Jbc.M114.565473 |
0.352 |
|
2014 |
Keiser MS, Boudreau RL, Davidson BL. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 588-95. PMID 24419082 DOI: 10.1038/Mt.2013.279 |
0.635 |
|
2014 |
Boudreau RL, Jiang P, Gilmore BL, Spengler RM, Tirabassi R, Nelson JA, Ross CA, Xing Y, Davidson BL. Transcriptome-wide discovery of microRNA binding sites in human brain. Neuron. 81: 294-305. PMID 24389009 DOI: 10.1016/J.Neuron.2013.10.062 |
0.756 |
|
2013 |
Rodríguez-Lebrón E, Costa MD, Luna-Cancalon K, Peron TM, Fischer S, Boudreau RL, Davidson BL, Paulson HL. Silencing Mutant ATXN3 Expression Resolves Molecular Phenotypes in SCA3 Transgenic Mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1909-1918. PMID 28157530 DOI: 10.1038/mt.2013.152 |
0.588 |
|
2013 |
RodrÃguez-Lebrón E, Costa Mdo C, Costa Md, Luna-Cancalon K, Peron TM, Fischer S, Boudreau RL, Davidson BL, Paulson HL. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1909-18. PMID 23820820 DOI: 10.1038/Mt.2013.152 |
0.631 |
|
2013 |
Keiser MS, Geoghegan JC, Boudreau RL, Lennox KA, Davidson BL. RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1. Neurobiology of Disease. 56: 6-13. PMID 23583610 DOI: 10.1016/J.Nbd.2013.04.003 |
0.636 |
|
2013 |
Boudreau RL, Spengler RM, Hylock RH, Kusenda BJ, Davis HA, Eichmann DA, Davidson BL. siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Research. 41: e9. PMID 22941647 DOI: 10.1093/Nar/Gks797 |
0.773 |
|
2012 |
Dissen GA, Lomniczi A, Boudreau RL, Chen YH, Davidson BL, Ojeda SR. Applying gene silencing technology to contraception. Reproduction in Domestic Animals = Zuchthygiene. 47: 381-6. PMID 23279544 DOI: 10.1111/Rda.12016 |
0.572 |
|
2012 |
Dissen GA, Lomniczi A, Boudreau RL, Chen YH, Davidson BL, Ojeda SR. Targeted gene silencing to induce permanent sterility. Reproduction in Domestic Animals = Zuchthygiene. 47: 228-32. PMID 22827375 DOI: 10.1111/J.1439-0531.2012.02080.X |
0.585 |
|
2012 |
Boudreau RL, Davidson BL. Generation of hairpin-based RNAi vectors for biological and therapeutic application. Methods in Enzymology. 507: 275-96. PMID 22365779 DOI: 10.1016/B978-0-12-386509-0.00014-4 |
0.618 |
|
2011 |
McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, Davidson BL. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 2152-62. PMID 22031240 DOI: 10.1038/Mt.2011.219 |
0.702 |
|
2011 |
Boudreau RL, Spengler RM, Davidson BL. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 2169-77. PMID 21952166 DOI: 10.1038/Mt.2011.185 |
0.787 |
|
2011 |
López-Tobón A, Castro-Álvarez JF, Piedrahita D, Boudreau RL, Gallego-Gómez JC, Cardona-Gómez GP. Silencing of CDK5 as potential therapy for Alzheimer's disease. Reviews in the Neurosciences. 22: 143-52. PMID 21476938 DOI: 10.1515/Rns.2011.015 |
0.424 |
|
2011 |
Boudreau RL, RodrÃguez-Lebrón E, Davidson BL. RNAi medicine for the brain: progresses and challenges. Human Molecular Genetics. 20: R21-7. PMID 21459775 DOI: 10.1093/Hmg/Ddr137 |
0.56 |
|
2011 |
Spencer NY, Yan Z, Boudreau RL, Zhang Y, Luo M, Li Q, Tian X, Shah AM, Davisson RL, Davidson B, Banfi B, Engelhardt JF. Control of hepatic nuclear superoxide production by glucose 6-phosphate dehydrogenase and NADPH oxidase-4. The Journal of Biological Chemistry. 286: 8977-87. PMID 21212270 DOI: 10.1074/Jbc.M110.193821 |
0.432 |
|
2011 |
Boudreau RL, Garwick-Coppens SE, Liu J, Wallace LM, Harper SQ. Rapid cloning and validation of MicroRNA shuttle vectors: A practical guide Neuromethods. 58: 19-37. DOI: 10.1007/978-1-61779-114-7_2 |
0.576 |
|
2010 |
Piedrahita D, Hernández I, López-Tobón A, Fedorov D, Obara B, Manjunath BS, Boudreau RL, Davidson B, Laferla F, Gallego-Gómez JC, Kosik KS, Cardona-Gómez GP. Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 13966-76. PMID 20962218 DOI: 10.1523/Jneurosci.3637-10.2010 |
0.537 |
|
2010 |
Boudreau RL, Davidson BL. RNAi therapeutics for CNS disorders. Brain Research. 1338: 112-21. PMID 20307511 DOI: 10.1016/J.Brainres.2010.03.038 |
0.62 |
|
2009 |
Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1053-63. PMID 19240687 DOI: 10.1038/Mt.2009.17 |
0.702 |
|
2009 |
Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 169-75. PMID 19002161 DOI: 10.1038/Mt.2008.231 |
0.605 |
|
2008 |
Boudreau RL, Monteys AM, Davidson BL. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. Rna (New York, N.Y.). 14: 1834-44. PMID 18697922 DOI: 10.1261/Rna.1062908 |
0.617 |
|
2008 |
McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ, Davidson BL. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proceedings of the National Academy of Sciences of the United States of America. 105: 5868-73. PMID 18398004 DOI: 10.1073/Pnas.0801775105 |
0.791 |
|
2007 |
Davidson BL, Boudreau RL. RNA interference: a tool for querying nervous system function and an emerging therapy. Neuron. 53: 781-8. PMID 17359914 DOI: 10.1016/J.Neuron.2007.02.020 |
0.627 |
|
2006 |
Boudreau RL, Davidson BL. RNAi therapy for neurodegenerative diseases. Current Topics in Developmental Biology. 75: 73-92. PMID 16984810 DOI: 10.1016/S0070-2153(06)75003-7 |
0.619 |
|
2006 |
Boudreau RL, Davidson BL. 90. miRNA Shuttles Improve Therapeutic RNAi Molecular Therapy. 13: S37. DOI: 10.1016/J.Ymthe.2006.08.108 |
0.647 |
|
2004 |
Boudreau R, Xia H, Davidson BL. 207. Micro RNAs as Novel siRNA Shuttles Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.148 |
0.654 |
|
Show low-probability matches. |